Q3 2023 · 13F-HR
Venrock Adviser, LLCholdings as filed
Filed 2023-11-14 · accession 0001104659-23-118127
$949.9M
Reported value
37
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $180.9M | 19.0% | 8,493,321 | Common | SOLE |
| 75525N107 | — | RAYZEBIO INC | $89.2M | 9.39% | 4,016,847 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $47.3M | 4.98% | 3,082,622 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $45.7M | 4.81% | 4,684,167 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $45.6M | 4.80% | 14,444,444 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $40.7M | 4.28% | 1,726,214 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $40.4M | 4.25% | 2,954,902 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $38.2M | 4.02% | 3,000,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $32.6M | 3.43% | 1,563,513 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $30.0M | 3.16% | 1,973,253 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $28.1M | 2.96% | 2,916,667 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $27.6M | 2.90% | 2,744,125 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $27.4M | 2.88% | 2,037,313 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $27.2M | 2.86% | 7,184,865 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $25.0M | 2.63% | 1,090,000 | Common | SOLE |
| 02290A102 | — | AMBRX BIOPHARMA INC | $23.8M | 2.51% | 2,070,000 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $23.5M | 2.47% | 2,623,677 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $19.5M | 2.05% | 2,173,913 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $19.2M | 2.03% | 2,105,386 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $15.6M | 1.64% | 3,092,273 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $14.4M | 1.51% | 11,328,000 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $14.1M | 1.48% | 5,658,034 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $13.0M | 1.36% | 2,142,856 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $12.7M | 1.33% | 927,706 | Common | SOLE |
| 00773U108 | ADVMCHF | ADVERUM BIOTECHNOLOGIES INC | $9.9M | 1.04% | 6,573,300 | Common | SOLE |
| 74006W108 | — | PRAXIS PRECISION MEDICINES I | $9.1M | 0.95% | 5,304,410 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $8.8M | 0.93% | 864,332 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $7.5M | 0.79% | 3,422,397 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $7.1M | 0.75% | 1,040,754 | Common | SOLE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $6.8M | 0.72% | 2,208,812 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $5.0M | 0.53% | 288,949 | Common | SOLE |
| 786700104 | SGMT | SAGIMET BIOSCIENCES INC | $4.5M | 0.48% | 515,000 | Common | SOLE |
| 00773J103 | — | AEGLEA BIOTHERAPEUTICS INC | $3.6M | 0.38% | 295,034 | Common | SOLE |
| 55234L105 | LYRAGBP | LYRA THERAPEUTICS INC | $3.6M | 0.38% | 924,170 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $951,469 | 0.10% | 77,042 | Common | SOLE |
| 75120L100 | — | RALLYBIO CORP | $904,953 | 0.10% | 268,532 | Common | SOLE |
| N01045108 | — | AFFIMED N V | $682,714 | 0.07% | 1,428,571 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.